\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Hyperuricemia in Type 2 Diabetes Mellitus}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2014-01-15 (revised: 15 January 2014)} \def\TheID{\makeatother } \def\TheDate{2014-01-15} \title{Hyperuricemia in Type 2 Diabetes Mellitus} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Kashinath R.T.} \author[2]{nagendra subbaiah } \affil[1]{ } \renewcommand\Authands{ and } \date{\small \em Received: 15 December 2013 Accepted: 1 January 2014 Published: 15 January 2014} \maketitle \begin{abstract} Recently there has been a growing interest in the association of uric acid levels with hyperglycemia. Insulin deficiency or subnormal functioning of insulin may induce possible alterations in purine nucleotide metabolism, specifically uric acid turnover. Studies have indicated that a close relationship do exists between plasma uric acid levels and glucose utilisation in type 2 diabetes mellitus. Though there are reports showing elevated plasma uric acid levels in type 2 diabetes mellitus but the origin of raised uric acid is still obscure. Hence a study was undertaken to assess the origin of raised plasma uric acid levels in diabetes mellitus. The type 2 diabetic subjects attending the OPD of Subbaiah Medical College Hospital, Purale, Shimoga were randomly selected. A fasting Blood sample was collected and the plasma samples were employed for estimation of glucose, uric acid, adenosine deaminase and 5'-nucleotidase levels.The results indicate a parallel raise in the plasma levels of adenosine deaminase and in 5'nucleotidase along with plasma uric acid levels in type 2 diabetic subjects suggesting the raised plasma uric acid in type 2 diabetic subjects is due to increased purine catabolism. \end{abstract} \keywords{type 2 diabetes mellitus, plasma uric acid, ada, 5'-nucleotidase.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{I.}]{I.}\par Introdouction nsulin deficiency as observed in type-2 diabetes mellitus apart from inducing disturbances in glucose and fat metabolism may also cause possible alterations in nucleotide metabolism, specifically in uric acid turnover. Uric acid, the end product of purine metabolism, is produced by the degradation of purine nucleotides and purine nucleosides with the help of degradativeenzymes, 5' Nucleotidaseadenosinedeaminase, nucleosidephosphorylase and xanthine oxidase. Since the time our pioneer observation regarding the raised blood uric acid levels in diabetic subjects \hyperref[b0]{(1)}, many reports have appeared showing a relationship of plasma uric acid levels with hyperglycemia \hyperref[b1]{(2)}\hyperref[b2]{(3)}\hyperref[b3]{(4)}\hyperref[b4]{(5)}\hyperref[b5]{(6)}\hyperref[b6]{(7)}\hyperref[b7]{(8)}\hyperref[b9]{(9)}\hyperref[b10]{(10)}\hyperref[b11]{(11)}\hyperref[b12]{(12)}\hyperref[b13]{(13)}\hyperref[b14]{(14)}\hyperref[b15]{(15)}\hyperref[b16]{(16)}\hyperref[b17]{(17)}. Many research workers \hyperref[b1]{(2)}\hyperref[b2]{(3)}\hyperref[b3]{(4)}\hyperref[b4]{(5)}\hyperref[b5]{(6)}\hyperref[b6]{(7)}\hyperref[b7]{(8)}\hyperref[b9]{(9)}\hyperref[b10]{(10)}\hyperref[b11]{(11)}\hyperref[b12]{(12)}\hyperref[b13]{(13)}\hyperref[b14]{(14)}\hyperref[b15]{(15)} suggest a positive correlation between plasma uric acid levels and diabetes mellitus while few reports advocate no such correlation \hyperref[b16]{(16,}\hyperref[b17]{17)}. The specific observation of Feldmann \& Lebrovitz \hyperref[b19]{(18)}, that ammonium ion (NH 4 + ) do modulate the glucose induced insulin secretion /action relates nucleotide metabolism to insulin action, as ammonia is a bye-product of purine nucleotide degradation.\par Hence a study was planned to reassess the plasma uric acid levels in diabetic subjects as well as to establish the possible origin of the raised plasma uric acid levels in type 2 diabetic subjects. \section[{II.}]{II.} \section[{Materials and Methods}]{Materials and Methods}\par All the chemicals and reagents employed in the present study were of analar grade, and the adenosine as well as AMP (Adenosine mono phosphate) (kindly donated by Dr. Aski, B M Patil Medical College, BLDE University, Bijapur, Karnataka, India) were of chromatographic purity.\par The type 2 diabetic subjects(both sexes) attending the medical OPD of Subbaiah Medical College Hospital ,Purle, Shimoga, who were in the age group of 30-60 years were randomly selected. Age matched normal subjects were selected from the employees of medical college and from medical college hospital. The subjects having orthopedic problems were excluded from the study. A fasting blood sample from both the normal as well as diabetic subjects were collected (4-5ml) with heparin as an anticoagulant after obtaining an informed consent from them. These blood samples were centrifuged for about 6-8 minutes at 3500rpm.\par The separated clear plasma was employed for estimation of glucose \hyperref[b20]{(19)}, uric acid \hyperref[b21]{(20)}, Adenosine deaminase (ADA) (21) and 5'-Nucleotidase \hyperref[b23]{(22)} levels. The results obtained were statistically analysed and the significance were calculated using Student't' test. \section[{III.}]{III.} \section[{Results}]{Results}\par A total number of 224 subjects including 120 diabetic and 104 normal subjects were employed in the present study. The diabetic subjects included 72 male diabetics and 48 female diabetic subjects. The normal subjects included 60 male and 44 female subjects. These diabetic subjects when divided age wise, there were 52 diabetic subjects in the age group of 30-50years and 68 diabetic subjects were above the age of 50years. Further these diabetic subjects were including 61 diabetics with positive family history of diabetes and 63 without family history of diabetes. This distribution of subjects are given in chart 1. The results obtained in the present study are depicted in table \hyperref[tab_0]{1} \hyperref[tab_1]{2} gives the plasma levels of glucose, uric acid,ADA and 5'-Nucleotidasein normal male subjects and in type 2diabetic subjects. It is clear from the table that all the parameters studied are significantly elevated in male diabetic subjects as compared to normal male subjects(p>0.001).\par Table \hyperref[tab_2]{3} gives the plasma levels of glucose, uric acid,ADA and5'-Nucleotidase in normal female subjects and in type 2diabetic female subjects. It is evident from the table that all the parameters studied are significantly elevated in diabetic female subjects as compared to normal female subjects(p>0.001). \hyperref[tab_5]{6} narrates the plasma levels of glucose, uric acid,ADA and 5'-Nucleotidase in diabetic subjects of 30-50years of age group and in diabeticsubjects above the age of 50years(Table \hyperref[tab_4]{5})as well as in diabetic subjects with positive family history of diabetes mellitus and in diabeticsubjects without any family history of diabetes mellitus (Table \hyperref[tab_5]{6}). As seen from the tables no significant variations observed between diabeticsubjects of different age groups as well as between the diabeticsubjects with positive family history of diabetes mellitus as compared to diabeticsubjects without any such diabetic history.\par Note: 1. The number in parenthesis shows the number of samples 2. Values are expressed as their Mean + SD 3. p-value*p<0.05, *p<0.01, *** p< 0.001. \section[{IV.}]{IV.} \section[{Discussion}]{Discussion}\par Starting with the first observation \hyperref[b0]{(1)}, showing the increased whole blood uric acid levels in diabeticsubjects, several reports have been presented suggesting a relationship between the uric acid levels and hyperglycemia in diabetic subjects \hyperref[b1]{(2)}\hyperref[b2]{(3)}\hyperref[b3]{(4)}\hyperref[b4]{(5)}\hyperref[b5]{(6)}\hyperref[b6]{(7)}\hyperref[b7]{(8)}\hyperref[b9]{(9)}\hyperref[b10]{(10)}\hyperref[b11]{(11)}\hyperref[b12]{(12)}\hyperref[b13]{(13)}\hyperref[b14]{(14)}\hyperref[b15]{(15)}\hyperref[b16]{(16)}\hyperref[b17]{(17)}. Many reports advocating a raise in plasma uric acid levels in diabetic subjects \hyperref[b1]{(2)}\hyperref[b2]{(3)}\hyperref[b3]{(4)}\hyperref[b4]{(5)}\hyperref[b5]{(6)}\hyperref[b6]{(7)}\hyperref[b7]{(8)}\hyperref[b9]{(9)}\hyperref[b10]{(10)}\hyperref[b11]{(11)}\hyperref[b12]{(12)}\hyperref[b13]{(13)}\hyperref[b14]{(14)}\hyperref[b15]{(15)} while few negate such observation \hyperref[b16]{(16,}\hyperref[b17]{17)}. The significant enzymes, which are quite abundant in tissues, responsible for the purine degradation are Adenosinedeaminase (Adenosine amino hydrolase EC: 3, 5, 4, 4) and 5'-Nucleotidase (5' nucleotide phosphohydrolase EC: 3, 1, 3, 5). Adenosinedeaminase is implicated in inflammatory conditions as well as in micro and macro vascular complications of diabetes mellitus \hyperref[b24]{(23)}. Similarly 5' nucleotidase has been claimed elevated in type 2 diabetes mellitus \hyperref[b25]{(24)}. Adenosine mimics the action of insulin on glucose and lipid metabolism in adipose tissue as well as in myocardium, while it inhibits the insulin effect on total hepatic glucose output suggesting that adenosine causes local insulin resistance in liver tissue. Adenosine modulates the action of insulin on various tissues differently and its tissue concentration is affected by ADA levels \hyperref[b26]{(25,}\hyperref[b37]{26)}. A parallel rise in the enzyme activities of adenosine deaminase and 5'-Nucleotidase in plasma, which may be due to an increase in their levels in the tissues, along with a rise in plasma uric acid levels suggest that the rise in plasma uric acid observed in the present study in type 2 diabetic subjects may be due to increased degradation of purine nucleosides and nucleotides. Kurtul N etal \hyperref[b38]{(27)}have shown increased level of serum ADA activity in type 2 diabetic subjects with its correlation to HbA1c and suggested that ADA is important enzyme for modulating the bioactivity of insulin.\par Subnormal insulin levels or insulin resistance seen in type 2 diabetes mellitus may decrease the activity of many glycolytic and citric acid cycle enzymes as insulin is a known promoter of the activities of pyruvatedehydrogenase, hexokinase, phosphofructokinase, pyruvatekinase, ?-ketoglutaratedehydrogenase etc \hyperref[b27]{(28)}. Such a decrease in the activity of these enzymes leads to accumulation of glucose-6phosphate, which may be channeled through HMP pathway causing an increase in ribose-5-phosphate which is the starting compound for purine biosynthesis. Thus purine synthesis increases resulting in an elevated formation of uric acid.\par It is known that the end regulation of insulin action is achieved through regulating protein-tyrosine phosphstases (PTP) which are thiol enzymes \hyperref[b28]{(29,}\hyperref[b29]{30,}\hyperref[b30]{31)}. One of the optimistic speculation is that the tissues and cells do try to adjust to the insulin deficiency state by prolonging the insulin action through regulating these PTPs by generating little amount of free oxygen species and these oxygen species in turn try to slow down the activity of PTPs by reacting with their free thiol groups. A possible reaction to generate oxygen species is purine degradation. A rise in plasma uric acid levels seen in the present study in type 2 diabetic subjects do support this speculation. This rise in plasma uric acid levels in diabetic subjects may also due to deterioration of glucose metabolism which is primarily due to insulin insufficiency as it is suggested by many research workers that increased plasma uric acid levels do correlate with deterioration of glucose metabolism in type 2 diabetic subjects \hyperref[b39]{(32,}\hyperref[b31]{33)}.\par The rise in plasma uric acid levels in type 2 female diabetic subjects is more pronounced as compared to type 2 male diabetic subjects (ref table \hyperref[tab_3]{4}) is in agreement with the earlier reports \hyperref[b33]{(34,}\hyperref[b34]{35)} and which may be due to estrogen, as estrogen is known to influence secretion of adrenal steroids which inturn influences the catabolism of nucleotides and nucleic acids \hyperref[b35]{(36,}\hyperref[b36]{37)}. No much variations are seen in the levels of uric acid, ADA and 5'-Nucleotidasein diabetic subjects of 30-50 yrs of age group as compared to diabetic subjects of above 50yrs age group (ref table \hyperref[b4]{5)} as well between diabetic subjects with positive family history as compared to diabetic subjects without any diabetic family history (ref table \hyperref[tab_5]{6}).\par It is concluded from the results of the present study in type 2 diabetic subjects that there is a definite rise in plasma uric acid levels in these diabetic subjects as compared to their normal counterparts and the uric acid elevation is due to increased degradation of purines as evidenced by the rised activity of Adenosine deaminase and 5'-Nucleotidase. \section[{Volume XIV Issue III Version I}]{Volume XIV Issue III Version I}\par Year 2014 ( B )\begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.85\textwidth}} to table 6.\end{longtable} \par {\small\itshape [Note: and in type 2 diabetic subjects. It is evident from the table that a significant raise is seen in plasma levels of]} \caption{\label{tab_0}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.44724517906336086\textwidth}P{0.08898071625344353\textwidth}P{0.08429752066115702\textwidth}P{0.11942148760330579\textwidth}P{0.11005509641873278\textwidth}} \tabcellsep Glucose\tabcellsep Uric acid\tabcellsep Adenosine deaminase units/L.\tabcellsep 5 ' -Nucleotidaseunits/100ml.\\ \tabcellsep mg/dl\tabcellsep mg/dl\tabcellsep \tabcellsep \\ Normal\tabcellsep 72.20\tabcellsep 5.62\tabcellsep 12.20\tabcellsep 6.8\\ male\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ subjects\tabcellsep 12.42\tabcellsep 1.18\tabcellsep 3.60\tabcellsep 1.0\\ (60)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Diabetic\tabcellsep 208.80***\tabcellsep 10.82***\tabcellsep 27.90***\tabcellsep 36.0***\\ male\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ subjects\tabcellsep 16.12\tabcellsep 2.22\tabcellsep 7.80\tabcellsep 9.0\\ (72)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{4}{l}{Note: 1. The number in parenthesis shows the number of samples}\tabcellsep \\ \multicolumn{4}{l}{2. Values are expressed as their Mean + SD}\tabcellsep \\ \multicolumn{4}{l}{3. p value*p<0.05, *p<0.01, *** p< 0.001.}\tabcellsep \end{longtable} \par \caption{\label{tab_1}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3} \par \begin{longtable}{P{0.31065989847715736\textwidth}P{0.09492385786802031\textwidth}P{0.2027918781725888\textwidth}P{0.12296954314720811\textwidth}P{0.11865482233502538\textwidth}} Year 2014\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ 20\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Volume XIV Issue III Version I\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ ( )\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Medical Research\tabcellsep \tabcellsep \multicolumn{3}{l}{female subjects and type 2 diabetic female subjects}\\ Normal female subjects (44) Diabetic female subjects (48) Note: 1. Global Journal of\tabcellsep Glucose mg/dl 74.80 + 6.80 212.62*** + 12.20\tabcellsep Uric acid mg/dl 5.62 + 1.22 11.30*** + 1.80\tabcellsep Adenosine deaminase units/L. 11.80 + 2.10 28.20*** + 6.60\tabcellsep 5 ' -Nucleotidase units/100ml. 7.0 + 2.2 37.1*** + 6.60\end{longtable} \par {\small\itshape [Note: BTable]} \caption{\label{tab_2}Table 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{P{0.45661157024793386\textwidth}P{0.08663911845730028\textwidth}P{0.07961432506887052\textwidth}P{0.11239669421487604\textwidth}P{0.11473829201101929\textwidth}} \tabcellsep Glucose\tabcellsep Uric acid\tabcellsep Adenosine deaminase units/L.\tabcellsep 5 ' -Nucleotidase units/100ml.\\ \tabcellsep mg. \%\tabcellsep mg.\%\tabcellsep \tabcellsep \\ Diabetic\tabcellsep 208.80\tabcellsep 10.82\tabcellsep 25.84\tabcellsep 36.0\\ male\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ Subjects\tabcellsep 16.12\tabcellsep 2.22\tabcellsep 5.36\tabcellsep 9.00\\ (72)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Diabetic\tabcellsep 212.62\tabcellsep 11.30\tabcellsep 28.20\tabcellsep 37.10\\ Female\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ subjects\tabcellsep 12.20\tabcellsep 1.80\tabcellsep 6.60\tabcellsep 6.60\\ (48)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{4}{l}{Note: 1. The number in parenthesis shows the number of samples}\tabcellsep \\ \multicolumn{4}{l}{2. Values are expressed as their Mean + SD}\tabcellsep \\ \multicolumn{4}{l}{3. p-value*p<0.05, *p<0.01, *** p< 0.001.}\tabcellsep \end{longtable} \par \caption{\label{tab_3}Table 4 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{5} \par \begin{longtable}{P{0.4520231213872832\textwidth}P{0.08352601156069364\textwidth}P{0.0810693641618497\textwidth}P{0.11791907514450865\textwidth}P{0.11546242774566473\textwidth}} Age Group\tabcellsep Glucose mg. \%\tabcellsep Uric acid mg.\%\tabcellsep Adenosine deaminase units/L.\tabcellsep 5 ' -Nucleotidaseunits/100ml.\\ 30-50\tabcellsep 210.6\tabcellsep 11.7\tabcellsep 25.02\tabcellsep 27.0\\ Years\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ (52)\tabcellsep 16.8\tabcellsep 3.10\tabcellsep 4.82\tabcellsep 5.50\\ Above\tabcellsep 222.4\tabcellsep 11.6\tabcellsep 22.88\tabcellsep 26.5\\ 50\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ Years\tabcellsep 22.6\tabcellsep 3.32\tabcellsep 5.66\tabcellsep 6.00\\ (68)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{4}{l}{Note: 1. The number in parenthesis shows the number of samples}\tabcellsep \\ \multicolumn{4}{l}{2. Values are expressed as their Mean + SD}\tabcellsep \\ \multicolumn{4}{l}{3. p-value*p<0.05, *p<0.01, *** p< 0.001.}\tabcellsep \end{longtable} \par \caption{\label{tab_4}Table 5 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{6} \par \begin{longtable}{P{0.22320143884892082\textwidth}P{0.10089928057553957\textwidth}P{0.09784172661870504\textwidth}P{0.14676258992805755\textwidth}P{0.28129496402877696\textwidth}} \tabcellsep \tabcellsep \tabcellsep \tabcellsep Year 2014\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep Volume XIV Issue III Version I\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep ( B )\\ Age\tabcellsep Glucose\tabcellsep Uric acid\tabcellsep Adenosine deaminase units/L.\tabcellsep 5 ' -Nucleotidase units/100ml.\\ Group\tabcellsep mg. \%\tabcellsep mg.\%\tabcellsep \tabcellsep \\ Diabetics\tabcellsep 208.8\tabcellsep 10.9\tabcellsep 28.12\tabcellsep 28.5\\ with family\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ history\tabcellsep 18.6\tabcellsep 2.80\tabcellsep 5.16\tabcellsep 6.90\\ (61)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Diabetics\tabcellsep 220.6\tabcellsep 10.8\tabcellsep 26.32\tabcellsep 30.5\\ Without\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ family history\tabcellsep 22.8\tabcellsep 1.20\tabcellsep 4.12\tabcellsep 5.80\\ (63)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par {\small\itshape [Note: © 2014 Global Journals Inc. (US)]} \caption{\label{tab_5}Table 6 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{} \end{longtable} \par \caption{\label{tab_6}Table 4}\end{figure} \begin{figure}[htbp] \noindent\textbf{5} \par \begin{longtable}{} \end{longtable} \par \caption{\label{tab_7}Table 5 \&}\end{figure} \footnote{© 2014 Global Journals Inc. (US) HYPERURICEMIA IN TYPE 2 DIABETES MELLITUS} \footnote{© 2014 Global Journals Inc. (US)} \backmatter \begin{bibitemlist}{1} \bibitem[Diabetes]{b8}\label{b8} \textit{}, Diabetes . \textit{Diabetologia} 12 p. . \bibitem[ Nitte University Journal of Health Science]{b32}\label{b32} \textit{}, \textit{Nitte University Journal of Health Science} 2 (2) p. . \bibitem[Feldman Jerome &heroldlebrovitz ()]{b19}\label{b19} \textit{}, Feldman Jerome \&heroldlebrovitz . \textit{Clin. Res} 1971. 19 (2) p. 474. \bibitem[Herman and Medelie ()]{b7}\label{b7} \textit{}, J B Herman , J Medelie . 1976. \bibitem[Nan et al. ()]{b39}\label{b39} \textit{}, Hairong Nan , Shaojie Zengchangpang , Wang , Weignogao , Leizang , Jieren , Jakko Fengning , Tuomilehto \& Qing , Qiao . \textit{Diabetes \& Vascular Disease Research} 2010. 7 (1) p. . \bibitem[Shankar ()]{b17}\label{b17} \textit{}, Pavanibhandari\&anoop Shankar . 2011. \bibitem[Wang et al. ()]{b4}\label{b4} ‘A prospective study on relationship between blood uric acid levels, insulin sensitivity and insulin resistance’. M Wang , O Zhao , W Wang , J \& Lin , S Lin . \textit{Chinese Journal of Internal Medicine} 2007. 46 p. . \bibitem[Goen et al. ()]{b37}\label{b37} ‘A study of serum adenosoinedeaminaselevels in patients with type 2 diabetes mellitus and its correlation with glycemic control. Ind’. M G Goen , H B Sirajwala , J Kalaria , K \&kamaria C P . \textit{J. Med. App. Sci} 2013. 2 (3) p. . \bibitem[Sudhindrarao and Sahayo ()]{b31}\label{b31} \textit{A study of Serum uric acid in diabetes mellitus and pre-diabetes in a south Indian tertiary care hospital}, M \&bino John Sudhindrarao , Sahayo . 2012. \bibitem[Ronald et al. ()]{b25}\label{b25} ‘Adenine nucleotide metabolism in hearts of diabetic rats’. L Ronald , Jenkins , G Huey , Stanley Mcdaneil , Wayne Digerness , \& Parrish , L Richard , Ong . \textit{Diabetes} 1988. 37 p. . \bibitem[Kurtel et al. ()]{b38}\label{b38} ‘Adenosine deaminase activity in lymphocytes’. N Kurtel , S Pence , E Akarsu , Etal . \textit{Br. J. Haematol} 1977. 37 p. . \bibitem[Kodama et al. ()]{b15}\label{b15} ‘Association between serum uric acid and development of type 2 diabetes’. S Kodama , K Saih , Y Yachi , Etal . \textit{Diabetes Care} 2009. 32 (9) p. . \bibitem[Association between serum uric acid levels and diabetes mellitus. I J. Endocrinol]{b18}\label{b18} ‘Association between serum uric acid levels and diabetes mellitus. I’. \textit{J. Endocrinol} 2011 p. . \bibitem[Safi and Mohmood ()]{b33}\label{b33} ‘Association of Serum uric acid with type 2 diabetes mellitus’. Abdul Jalai Safi , Rashid Mohmood . \textit{JPMI} 2004. 18 (1) p. . (Mudassir Ahmed Khan \&Amin-ul-Haq) \bibitem[Brownlee ()]{b24}\label{b24} ‘Biochemistry and molecular cell biology of diabetic complications’. M Brownlee . \textit{Nature} 2001. 414 p. . \bibitem[Campbell ()]{b23}\label{b23} Campbell . \textit{Practical Clinical Biochemistry by HeroldVarley, 3 rd Edn}, 1967. p. . \bibitem[Caraway ()]{b21}\label{b21} T Caraway . \textit{Practical Clinical Biochemistry by HeroldVarley, 3 rd Edn}, 1967. p. 205. \bibitem[Quinones et al. ()]{b5}\label{b5} ‘Effect of insulin on uric acid excretion in humans’. G A Quinones , A Natali , S Baldi , S Frascerra , G Sanna , D Ciociaro , Etal . \textit{Am. J. Endocrinol. Metab} 1995. 268 p. . \bibitem[Modan et al.]{b16}\label{b16} ‘Elevated serum uric acid -a facet of hyperinsulinaemia’. M Modan , H Halkin , A Karasika . \textit{Diabetelogia} 30 (9) p. . \bibitem[Giusti ()]{b22}\label{b22} \textit{Estimation of adinosinedeaminase cited in Methods of enzymatic analysis}, G Giusti . 1974. Bergmeyer Hu Academic press inc. 2 p. . \bibitem[Warrior et al. ()]{b26}\label{b26} ‘Evaluation of adenosine deaminase activity and lipid peroxidation level in diabetes mellitus’. A C Warrior , N Y Rao , D S Kulpati , T Mishra , K \&kabi B C . \textit{Ind. J. Clin. Biochem} 1995. 10 (1) p. . \bibitem[Kertes and J &jhonson T M ()]{b1}\label{b1} \textit{Evidence based Eye care. Philidelphia}, P Kertes , J \&jhonson T M . 2007. Lippincott Williams \& Wilkins. \bibitem[Boyko et al. ()]{b11}\label{b11} ‘Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance -a prospective study in Maurtius’. E J Boyko , M De Courten , P Z Zimmer , P Chitson , K Tonmilhetoj\&alberti . \textit{Diabetes Care} 2000. 23 p. . \bibitem[Dehgan et al. ()]{b12}\label{b12} ‘High serum uric acid as a novel risk factor for type 2 diabetes’. A Dehgan , Von Hock , M Sjibrands , J G Hofman A \&whitteman C M . \textit{Diabetes Care} 2008. 31 (2) p. . \bibitem[Fao et al. ()]{b36}\label{b36} ‘Influence of prolactin on blood sugar in normal and depanreatised dogs’. P P Fao , G Galasino , H Wheinstein , A R \& Magill . \textit{Am. J. Physiol} 1955. 180 p. . \bibitem[Butturini and Coscelli ()]{b2}\label{b2} ‘Insulin release in hyperuricemic patients’. U Butturini , C Coscelli . \textit{Acta. Diabetol. Lat} 1977. 14 p. . \bibitem[Mahdev et al. ()]{b28}\label{b28} ‘Insulin stimulated hydrogen peroxide reversibly inhibits protein tyrosine phosphatases in vivo and enhances the early insulin action cascade’. K Mahdev , A Zilbering , L Zhu , B Goldstein . \textit{J. Biol. Chem} 2001. 276 p. . \bibitem[Medelie et al. ()]{b6}\label{b6} ‘Major factors in the development of diabetes mellitus in 10000 men’. J H Medelie , C M Papier , U \& Goldbourt , J Herman . \textit{Arch. Int. Med} 1975. 135 p. . \bibitem[Toumilehto et al. ()]{b9}\label{b9} ‘Plasma uric acid and its association with diabetes mellitus and some biological parameters in biracial population of Fizi’. J Toumilehto , P Zimmet , E Wolf , R Taylor , P \& Ram , H King . \textit{Am. J. Epidemiol} 1988. 127 p. . \bibitem[Chein et al. ()]{b13}\label{b13} ‘Plasma uric acid and risk of type 2 diabetes in Chinese community’. K L Chein , M E Chan , H Hsu . \textit{Clin. Chem} 2008. 54 p. . \bibitem[Practical Clinical Biochemistry by HeroldVarley, 4th Edn]{b20}\label{b20} \textit{Practical Clinical Biochemistry by HeroldVarley, 4th Edn}, p. . \bibitem[Fao et al. ()]{b35}\label{b35} ‘Prolactin and secretion of insulin and glucagon by the pancreas’. P P Fao , G \& Galasino , E Costa . \textit{Am. J. Physiol} 1955. 182 p. . \bibitem[Brein R M &granner D K ()]{b27}\label{b27} ‘Regulation of gene expression by insulin’. Brein R M \&granner D K . \textit{Biochem. J} 1991. 278 p. . \bibitem[Meng et al. ()]{b30}\label{b30} ‘Regulation of insulin signaling through reversible oxidation of the protein tyrosine phosphatases TC 45 and PTP1B’. T C Meng , D A Buckley , S Galic , T Tiganis , Nk . \textit{J.Biol. Chem} 2004. 279 p. . \bibitem[Meng et al. ()]{b29}\label{b29} ‘Reversible oxidation and inactivation of protein tyrosine phosphatase in vivo’. T C Meng , T Fukuda , Nk . \textit{Molecular Cell} 2002. 9 p. . \bibitem[Nakanishi et al. ()]{b10}\label{b10} ‘Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers’. N Nakanishi , M Okamoto , H Yoshida , Y Matsuo , K Suzuki K \&tatara . \textit{Eur. J. Epidemiol} 2003. 18 p. . \bibitem[Kramer et al. ()]{b14}\label{b14} ‘Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose -The Rancho Bernardo Study’. C K Kramer , D Van Muhlen , S Jassal , E \&barrot-Conner . \textit{Diabetes Care} 2009. 32 (7) p. . \bibitem[Sinagra et al. ()]{b3}\label{b3} ‘Serum uric acid, insulin secretion and resistance in non-hyperuricemia and hyperuricemic obese female subjects’. D Sinagra , D Greco , A Scarpitta . \textit{Int. J. Obes. Relat. Metab.Disord} 1996. 20 p. . \bibitem[Clark ()]{b34}\label{b34} ‘The uptake of P 32 by nucleic acids of Lymphoid tissue undergoing atrophy’. I D Clark . \textit{J. Biol. Chem} 1956. 222 p. . \bibitem[Kashinath ()]{b0}\label{b0} ‘Whole blood uric acid levels in diabetics with or without lipaemia’. R Kashinath . \textit{J. Mys. Med. Assoc} 1972. 36 p. . \end{bibitemlist} \end{document}